Compare KNOP & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNOP | BWAY |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 337.9M |
| IPO Year | 2013 | 2019 |
| Metric | KNOP | BWAY |
|---|---|---|
| Price | $10.40 | $19.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 121.8K | 67.9K |
| Earning Date | 12-04-2025 | 11-11-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 1.17 | 0.13 |
| Revenue | ★ $352,712,000.00 | $49,094,000.00 |
| Revenue This Year | $14.84 | $330.76 |
| Revenue Next Year | $1.98 | $22.24 |
| P/E Ratio | ★ $8.84 | $59.95 |
| Revenue Growth | 17.65 | ★ 27.08 |
| 52 Week Low | $5.28 | $7.84 |
| 52 Week High | $10.99 | $19.80 |
| Indicator | KNOP | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 63.56 |
| Support Level | $10.37 | $18.31 |
| Resistance Level | $10.64 | $19.80 |
| Average True Range (ATR) | 0.22 | 0.84 |
| MACD | -0.05 | 0.18 |
| Stochastic Oscillator | 30.92 | 83.16 |
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.